Please login to the form below

Not currently logged in
Email:
Password:

Amitiza

This page shows the latest Amitiza news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Efient and Sucampo's Amitiza win NICE backing

Lilly’s Efient and Sucampo's Amitiza win NICE backing

Lilly’ s Efient and Sucampo's Amitiza win NICE backing. Blood clot and constipation drugs recommended for NHS use. ... The Amitiza recommendation follows earlier draft guidance published in June that determined the drug was a cost effective treatment

Latest news

  • NICE backs constipation treatment NICE backs constipation treatment

    NICE backs constipation treatment. Sucampo’ s Amitiza set for NHS use in England and Wales. ... Sucampo's constipation treatment Amitiza (lubiprostone) should be available on the NHS, according to new healthcare guidance.

  • NICE backs constipation treatment NICE backs constipation treatment

    NICE backs constipation treatment. Sucampo’ s Amitiza set for NHS use in England and Wales. ... Sucampo's constipation treatment Amitiza (lubiprostone) should be available on the NHS, according to new healthcare guidance.

  • AZ drug for opioid constipation starts FDA review AZ drug for opioid constipation starts FDA review

    AZ drug for opioid constipation starts FDA review. Naloxegol on course to compete with Takeda’ s Amitiza. ... Sucampo reported Amitiza sales of a little over $80m in 2012 but that product is also tipped to reach $200m.

  • Sucampo-Takeda to file for US approval of Amitiza as OBD treatment

    It is estimated that 4.5m patients in the US suffer from OBD, so extending Amitiza's indications to include this use could dramatically increase sales. ... added. Sucampo is in the final stages of an arbitration process seeking to revise the terms of its

  • An unexpected turn

    Amitiza (Takeda Pharmaceuticals). Irritable Bowel Syndrome. US. Mycophenolate mofetil (Cellcept; Roche) is an immunosupressant commonly used for treating and preventing transplant rejection.

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics